Recombinant Human Transcriptional regulator ERG(ERG)

Code CSB-EP007781HU
Size US$1726
Image
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity Greater than 90% as determined by SDS-PAGE.
Target Names ERG
Uniprot No. P11308
Research Area Transcription
Alternative Names Avian erythroblastosis virus E-26 (v-ets) oncogene related; D030036I24Rik; Erg 3; Erg; ERG/EWS fusion gene; included; ERG/FUS fusion gene; included; ERG/TMPSSR2 fusion gene; included; ERG_HUMAN; ERG1; included; ERG2; included; ets related; ETS-related gene; KCNH2; Oncogene ERG; p55; TMPRSS2/ERG fusion; transcriptional regulator ERG (transforming protein ERG); Transcriptional regulator ERG; Transforming protein ERG; v ets avian erythroblastosis virus E26 oncogene; v ets avian erythroblastosis virus E26 oncogene related; v ets erythroblastosis virus E26 oncogene homolog; v ets erythroblastosis virus E26 oncogene like; v ets erythroblastosis virus E26 oncogene like isoform 2; v-ets erythroblastosis virus E26 oncogene; v-ets erythroblastosis virus E26 oncogene homolog (avian); V-ets erythroblastosis virus E26 oncogene like (Avian); isoform CRA_e
Species Homo sapiens (Human)
Source E.coli
Expression Region 1-486aa
Target Protein Sequence MIQTVPDPAAHIKEALSVVSEDQSLFECAYGTPHLAKTEMTASSSSDYGQTSKMSPRVPQQDWLSQPPARVTIKMECNPSQVNGSRNSPDECSVAKGGKMVGSPDTVGMNYGSYMEEKHMPPPNMTTNERRVIVPADPTLWSTDHVRQWLEWAVKEYGLPDVNILLFQNIDGKELCKMTKDDFQRLTPSYNADILLSHLHYLRETPLPHLTSDDVDKALQNSPRLMHARNTGGAAFIFPNTSVYPEATQRITTRPDLPYEPPRRSAWTGHGHPTPQSKAAQPSPSTVPKTEDQRPQLDPYQILGPTSSRLANPGSGQIQLWQFLLELLSDSSNSSCITWEGTNGEFKMTDPDEVARRWGERKSKPNMNYDKLSRALRYYYDKNIMTKVHGKRYAYKFDFHGIAQALQPHPPESSLYKYPSDLPYMGSYHAHPQKMNFVAPHPPALPVTSSSFFAAPNPYWNSPTGGIYPNTRLPTSHMPSHLGTYY
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight 70.6kDa
Protein Length Full Length
Tag Info N-terminal 6xHis-SUMO-tagged
Form Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA Please contact us to get it.

Target Data

Function Transcriptional regulator. May participate in transcriptional regulation through the recruitment of SETDB1 histone methyltransferase and subsequent modification of local chromatin structure.
Gene References into Functions
  1. endothelial transcriptional effector activated downstream of Ang1 to promote Notch signalling and vascular stability PMID: 28695891
  2. Nine primary prostate cancers that developed metachronous bone metastasis samples showed TMPRSS2-ERG fusions, which were associated with increased ERG expression at immunohistochemistry. mTOR pathway activation was documented in 6 patients PMID: 30190183
  3. Data indicate a significant prognostic role for assessing transcriptional regulator ERG (ERG) and phosphatase and tensin homolog protein (PTEN) in men with prostate cancer. PMID: 30101374
  4. There was no statistically significant difference in the expression of the ERG between patients and controls. Also, no correlation was detected between the expression of this gene and age of onset, disease duration and Expanded Disability Status Scale. PMID: 29488813
  5. Here, the authors show that ERG, through its physical interaction with androgen receptor, induces AR aggregation and endoplasmic reticulum stress in the prostate glands of ERG transgenic mice. PMID: 28439080
  6. Our results suggested that reduced expression of miR-1271 may be involved in the ERG expression and that miR-1271 could be a therapeutic target for ERG-positive prostate cancer patients PMID: 28551819
  7. Evaluating the association between ERG expression and pathologic factors. PMID: 29948147
  8. despite of their well-known adverse role in prognosis of AML, neither BAALC nor ERG expression levels at diagnosis had effect on survival of AML patients who underwent allo-HSCT. PMID: 29696374
  9. ERG expression is lost in liver endothelial cells from cirrhotic patients with fibrosis related to alcoholic liver disease or primary biliary cirrhosis and inversely correlates with increased markers of endothelial-to-mesenchymal transition. PMID: 29026072
  10. ERG expression is of limited prognostic value in acute myeloid leukemia. PMID: 27935581
  11. Our findings indicate that TGF-beta signaling is a major determinant of EMT in T/E overexpressing LNCaP cells. PMID: 28445989
  12. Findings reveal that PCa-associated ERG can interact and co-occupy with BRD4 in the genome, and suggest this druggable interaction is critical for ERG-mediated cell invasion and PCa progression. PMID: 27223260
  13. this work provides novel insights in the regulation of ERG protein stability in prostate cancer PMID: 27626314
  14. Study reveals that miR-200b/a/429 is an ERG target gene, which implicates an important role in TMPRSS2/ERG-dependent PCa development. PMID: 27191272
  15. ERG and SOX9 are potential biomarkers for prediction of response to docetaxel treatment in metastatic castration-resistant prostate cancer patients. PMID: 27863438
  16. A potential novel function of TMPRSS2-ERG as a major regulator of IGF1R gene expression. PMID: 27285981
  17. Study shows that T2E fusion transcripts are associated with higher levels of AMACR mRNA in patients with atypical small acinar proliferation (ASAP) which represents an indicator of risk for prostate cancer in patients with ASAP. PMID: 29277318
  18. TMPRSS2-ERG may have a role in progression of prostate neoplasms and in alteration of the metabolic profile PMID: 27276682
  19. Detection of TMPRSS2-ERG in blood from Metastatic Resistant Prostate Cancer patients predicts resistance to docetaxel and it may be useful to select treatment and to avoid possible toxicities in refractory patients.TMPRSS2-ERG-positive patients had more adverse prognostic factors compared with TMPRSS2-ERG-negative. PMID: 26948395
  20. Meta-analysis showed the prevalence of TMPRSS2:ERG fusions in prostate cancer to be highest in men of European descent (49%), followed by Asians (27%) and then African (25%) descent. PMID: 28633309
  21. Data show that tumors displaying TMPRSS2-ERG fusions that retained interstitial genes were less likely to be associated with biochemical recurrence PMID: 29127096
  22. ERG, FLI1, TAL1, and RUNX1 bind at all AML1-ETO-occupied regulatory regions, including those of the AML1-ETO gene itself, suggesting their involvement in regulating AML1-ETO expression levels. PMID: 27851970
  23. four oncogenic ETS (ERG, ETV1, ETV4, and ETV5), and no other ETS, interact with the Ewing's sarcoma breakpoint protein, EWS. PMID: 27783944
  24. We demonstrate a role for inflammation-induced oxidative stress in the formation of DNA breaks leading to recurrent TMPRSS2-ERG gene fusions. The transcriptional status and epigenetic features of the target genes influence this effect. PMID: 27926866
  25. ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the androgen receptor. PMID: 27183006
  26. NOTCH pathway inhibition antagonizes the growth and invasion of transmembrane protease serine 2 (TMPRSS2)-transforming protein ERG (ERG) (T2E) -positive prostate cancer cells. PMID: 28783165
  27. findings have identified critical molecular mechanisms involving ERK-mediated ERG activation that could be exploited for therapeutic intervention in ERG-positive prostate cancers. PMID: 28887309
  28. Detection of Gene Rearrangements in Circulating Tumor Cells: Examples of ALK-, ROS1-, RET-Rearrangements in Non-Small-Cell Lung Cancer and ERG-Rearrangements in Prostate Cancer.( PMID: 28560674
  29. The TMPRSS2-ERG gene fusion is the most frequently observed genetic aberration in Prostate cancer. PMID: 28845585
  30. Loss of ERG is associated with prostate tumors. PMID: 28186998
  31. Data show that homogeneous ERG positivity is very rare in prostate cancer, especially in elderly patients. However, development of subpopulations with ERG fusions may be a much more frequent event in ERG negative cancer foci as previously believed. PMID: 27530104
  32. Genome-wide gene expression profiling identified a network of VEGF-responsive and ERG-dependent genes. PMID: 28536097
  33. ERG deletion is associated with acute lymphoblastic leukemia. PMID: 27776115
  34. Study provide evidence that PTEN deletion and TMPRSS2-ERG gene fusion were mutually exclusive in patients with prostate neoplasm. TMPRSS2-ERG gene fusion was rare compared to peripheral zone tumors and to PTEN inactivation in T1a transition zone tumors. PMID: 27500376
  35. ERG rearrangement, but not PTEN loss, is present in a minority of potential neoplastic precursor lesions in the prostate. PMID: 27189342
  36. Patients with Prostate cancer had significantly higher levels of the prostate cancer-associated gene ERG in post-digital rectal examination urine extracellular vesicles. Continued analysis of urine EVs offers the potential discovery of novel biomarkers for pre-biopsy Prostate cancer detection. PMID: 28419548
  37. loss of ERG and FLI1 might contribute to the pathogenesis of vascular lung complications through the induction of inflammation. PMID: 28248553
  38. Neither the expression of aberrant proteins from internally deleted allele nor the reduced expression of wild type ERG seem to provide a plausible explanation of the specific biology of ERG -related leukemia subgroup. PMID: 27494621
  39. Our results suggest that the immune response may differ between ERG negative and ERG positive prostatic carcinomas PMID: 28547958
  40. identified five phosphorylated serines on endogenous ERG in T-ALL and AML cells. PMID: 27055868
  41. miR-204 upregulates androgen receptor (AR ) and downregulates TMPRSS2/ERG through direct regulation of their promoter methylation and set of transcription factors during AR cancer-related reprogramming. PMID: 28050800
  42. differential expression of TMPRSS2:ERG in urine exosomes in prostate cancer and controls PMID: 27144529
  43. SPINK1 and ERG expressions are exclusive events in PCA. PMID: 27738792
  44. This study focused on the clinical application value of ERG methylation level in blood of pregnant women as a biomarker in Down's syndrome. PMID: 28111453
  45. ETV6 and IKZF1 are transcriptional regulators not just of ERG, but also of a number of genes regulated by a densely interconnected network of seven transcription factors. PMID: 27604872
  46. Among 98 selected prostate carcinoma biopsies, 57 showed positive and 41 negative ERG staining. PMID: 28384107
  47. The present study established evidence for the first two common PrCa risk variants differentially associated with TMPRSS2:ERG fusion status. TMPRSS2:ERG phenotyping of larger studies is required to determine comprehensive sets of variants with subtype-specific roles in prostate cancer. PMID: 27798103
  48. ERG is recruited to mRNAs via interaction with the RNA-binding protein RBPMS, and it promotes mRNA decay by binding CNOT2, a component of the CCR4-NOT deadenylation complex. PMID: 27273514
  49. Concurrent nuclear ERG and MYC protein overexpression is common in prostate cancer and defines a subset of locally advanced tumors. PMID: 27159573
  50. Studies indicate that TMPRSS2-ERG fusion gene positive prostate cancers cells rewire intracellular signaling cascades and modulate gene and protein network. PMID: 28364793
  51. ERG protein expression shows almost complete concordance (98.2%) across cribriform and non-cribriform prostatic carcinomas. PMID: 27913052
  52. ERG (or FLI1 if available) is useful marker for the diagnosis of Phosphaturic mesenchymal tumors. PMID: 26122367
  53. These results suggested that miR145 might act as a tumor suppressor during the process of colorectal cancer malignant transformation by interacting with ERG. PMID: 27572146
  54. ERG promotes prostate tumorigenesis together with KDM4A through the upregulation of YAP1. A corollary is that KDM4A as well as YAP1 inhibitors may prove beneficial for the therapy of ERG-overexpressing prostate tumors. PMID: 27109047
  55. TMPRSS2-ERG role in prostate cancer invasiveness and regulation of MMP-9 and plexin B1. PMID: 28004109
  56. Our results indicate that it is possible to predict pT3 stage at final histology from TMPRSS2:ERG gene fusion at initial core needle biopsy. FISH determination of TMPRSS2:ERG gene fusion may be particularly useful for patients scheduled to undergo a radical prostatectomy in order to improve oncological and functional results PMID: 27377958
  57. Data show that significant associations between cyclin-dependent kinase inhibitor p16 upregulation and tumor phenotype or patient prognosis were strictly limited to the subset of transcriptional regulator ERG negative cancers. PMID: 27444279
  58. Data show there was a good agreement of transcriptional regulator ERG protein (ERG) immunostaining with the presence of TMPRSS2:ERG fusion protein. PMID: 27320318
  59. Data show a significant association between Alpha-methylacyl-CoA racemase (AMACR) and ERG protein with prognostic implication in prostate cancer. PMID: 27271990
  60. Elucidation of the mechanisms of ERG gene rearrangements and expression promises novel therapeutic and diagnostic avenues for prostate cancer PMID: 26711283
  61. A combination of high preoperative serum PSA and high expression of TMPRSS2-ERG could be promising in distinguishing those tumors that are aggressive and life-threatening. PMID: 27630329
  62. Data indicate that SPINK1 expression status shows a lower rate of concordance between primary prostate cancer (PCA) site and nodule metastases, than those of ERG and PTEN. PMID: 26725250
  63. ERG was not expressed in benign mimickers of prostate cancer biopsy samples. PMID: 27383878
  64. The study of biopsies from metastatic sites from patients with advanced prostate cancer has revealed potentially actionable or prognostic genomic alterations. Common genomic alterations observed in castration-resistant are: ERG gene fusion,AR gene point mutation or amplification , TP53 mutation or deletion,PTEN deletion, RB1 deletion and alterations in DNA repair genes PMID: 27249694
  65. Studies showed that urinary TMPRSS2:ERG transcripts seem to be indicative of Prostate cancer aggressiveness upon biopsy. [review] PMID: 26774207
  66. Report an altered cholesterol metabolism in more aggressive cancer types and an altered fatty acid oxidation in ERG-positive prostate tumors. PMID: 26623558
  67. ERG-fusion can precede 6q15 deletion and result in prostate cancer. PMID: 26684029
  68. Aspirin was associated with a significant reduction in the relative risk of TMPRSS2:ERG (T2E )fusion positive, but not T2E negative PMID: 26503111
  69. Approx 25% of discontinuously involved prostate biopsy cores showed tumor foci with discordant ERG/SPINK1 status, consistent with multiclonal disease. PMID: 26743468
  70. Results suggest that acquired gain of chromosome 21 or amplification of chromosome arm 21q is one mechanism contributing to increased ERG expression in acute myeloid leukemia. PMID: 26542308
  71. BAALC and ERG genes are specific significant molecular markers in acute myeloid leukemia disease progression, response to treatment and survival. PMID: 26625814
  72. prevalence of the FUS-ERG gene fusion in a large cohort of pathologically and molecularly well characterized small blue round cell tumors, lacking other known gene rearrangements PMID: 26690869
  73. prognostic power of proliferation markers PHH3 and Ki-67 was markedly enhanced in ERG translocation negative PMID: 26517642
  74. FUS-ERG is a transcriptional repressor of retinoic acid signaling. It acts in the context of a heptad of proteins (ERG, FLI1, GATA2, LYL1, LMO2, RUNX1 and TAL1) central to proper expression of genes maintaining a hematopoietic stem cell phenotype. PMID: 26148230
  75. Free testosterone was significantly associated with the risk of ERG-positive prostate cancer. PMID: 26986253
  76. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result PMID: 26345389
  77. We examined the correlation of clinicopathological factors and prognosis with ERG and the TMPRSS2-ERG fusion oncogene and ERG expression as predictive markers--REVIEW} PMID: 26452381
  78. The role of ERG oncogene in prostate cancer PMID: 25915839
  79. Overexpression of FLI1 and ERG genes is sufficient to transdifferentiate erythroblasts to megakaryocytes that can produce functional platelets. PMID: 26063314
  80. Data indicate that ERG has effects on cell metabolism and proliferation by increasing cell responsiveness to exogenous neurotransmitter receptor agonists such as nicotine, and possibly to endogenous neurotransmitters. PMID: 26310325
  81. Upregulation of ERG in 32D cells rescued miR-9/9*-induced block in neutrophil differentiation PMID: 26174629
  82. Data iindicate a different ratio of active transcription factor ERG's to ERG isofoprm ERG8 in cancer- versus non-transformed cells. PMID: 26554849
  83. The relatively low rate of ERG-positive prostatic intraepithelial neoplasia counts in favor of the limited role of chimeric transcript TMPRSS2/ERG in the differential diagnosis of prostatic intraepithelial neoplasia PMID: 26978019
  84. We conclude that flecainide accesses the hERG channel from the cell interior on channel gating, binding low in the inner cavity, with the S6 F656 residue acting as a principal binding determinant. PMID: 26159617
  85. Case Report: SMARCB1-deficient vulvar sarcoma expressing ERG and FLI1. PMID: 26261664
  86. ERG IHC is of limited additional diagnostic value when added to AMACR and CK5/6. ERG expression is inversely related to GS and is associated with bilateral involvement and higher PCA tumor volume. PMID: 25517865
  87. neither ERG nor SPINK1 appear to be useful biomarkers for prognostication of early stage prostate cancer PMID: 26172920
  88. The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition PMID: 26026052
  89. ERG expression was significantly less common among prostatic ductal adenocarcinomas compared to acinar carcinomas. PMID: 26178158
  90. ERG expression was not associated with risk of castration-resistant prostate cancer. PMID: 26053696
  91. results of our study argue against a tumor-promoting role of SOX9 in prostate cancer, but demonstrate that loss of SOX9 expression characterizes a particularly aggressive subset of ERG positive cancers harboring PTEN deletion PMID: 26030748
  92. TMPRSS2-ERG expression was detected in carcinoma foci, regions next to them, and in samples not adjacent to carcinoma foci; Molecular changes outside the carcinoma foci are also indicated for PCA3. PMID: 26294063
  93. miR-30b was involved in the process of osteoarthritis, and it probably functioned through its target gene ERG PMID: 26653555
  94. ERG-positive tumors increase in proportion with increasing stage of disease, but strength of ERG expression in ERG-positive patients shows a significant decline, or "loss," in patients with stage 4 disease. PMID: 25899828
  95. ERG overexpression was associated with favorable recurrence-free survival after radical prostatectomy for prostate cancer, whereas PTEN loss was associated with unfavorable outcomes. PMID: 25897494
  96. Results show the transcriptional repression of ANXA2 by ERG in prostate epithelial cells plays a critical role in abrogating differentiation, promoting epithelial-mesenchymal transition, and in the inverse correlation of expression seen in prostate tumor. PMID: 25344575
  97. The potential for TMPRSS2:ERG gene fusion, detected by IHC, to modify the role of PTEN loss in lethal progression of prostate cancer. PMID: 26615022
  98. Results indicate that PTEN loss occurs in cooperation with TMPRSS2-ERG fusion in prostate cancer and the majority of the samples harbor TMPRSS2-ERG fusion as well as PTEN gene deletion. PMID: 26424596
  99. ERG expression is variable in prostate cancer and is associated with activation of multiple pathways and proteins including several potentially targetable pathways. PMID: 25972242
  100. Elucidation of ERG regulation of ABEs in castration-resistant prostate cancer (CRPC) may help to stratify TMPRSS2-ERG fusion-positive prostate cancer patients in the clinic for anti-androgen receptor-driven therapies. PMID: 25754347

Show More

Hide All

Involvement in disease Ewing sarcoma (ES)
Subcellular Location Nucleus, Cytoplasm
Protein Families ETS family
Database Links

HGNC: 3446

OMIM: 165080

KEGG: hsa:2078

STRING: 9606.ENSP00000381891

UniGene: Hs.473819

Most popular with customers

  Tel: 301-363-4651
  Email: support@cusabio.com
  Distributors Worldwide

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1